WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

https://www.wuxibiologics.com/upload/202104/27/ar2020.pdf 2020 Annual Report

👋

Morgen 😎

US  Stocks Jumble; WUXI BIO (02269 HK) Worth Buy-on-dip http://www.aastocks.com/en/stocks/news/aafn-con/.HK.210427_103045/company-news Daiwa Upbeat on WUXI BIO (02269 HK)'s Growth Outlook despite Key Shareholder Unloading http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1094278/company-news

WuXi Biologics reduced its holdings of approximately HK$11.6 billion by major shareholders and its shareholding ratio will drop to 17.44% https://www.reuters.com/article/wuxi-bio-0427-tues-idCNKBS2CE01N

Chinese CDMO sector growing but unlikely to make global impact https://bioprocessintl.com/bioprocess-insider/global-markets/chinese-cdmo-sector-growing-but-unlikely-to-make-global-impact/ China’s contract manufacturing space is growing at over 15% year-on-year but only WuXi Biologics has seen success in attracting global clients, says BioPlan Associates ahead of CPhI Discover. ...

WUXI BIO's Key Shareholder Mulls Placing Shrs at 5.9-8.5% Discount to Raise Up to $10.58B http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1094077/hk-stock-news

Läuft gut aktuell

G Sachs' Latest Ratings & TPs on CN Drug Developers/ Agents  http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1092720/hk-stock-news Stocks｜Ratings｜TPs (HK$) WUXI BIO   Buy    128.6→131.4

Daiwa refers to WuXi Biologics (02269-HK) with strong revenue growth in the next two years, target price raised to HK$140 https://www.finet.hk/newscenter/news_content/607e2c79bde0b31a56b2a902

CICC: PRC's Vaccination Rate May Keep Rising in 2Q21, Eyes State-Owned Drugmakers' Valuation Recovery http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1092379/hk-stock-news CICC foresaw in its report that China's 2Q21 vaccination rate will hopefully keep rising as Beijing further encourages citizens to be vaccinated with a higher vaccine output. The broker encouraged readers to eye state-owned drugmakers' valuation recovery and preferred WUXI BIO (02269 HK), ...

👍🏼

Schönes Wochenende

Der Bericht ist etwas länger, wieder ein Fall für den Übersetzer und lässt sich auch ohne die App öffnen und lesen. Am Anfang geht es um WuXi Bio und später um die AppTec. Nicht viel neues, eher eine Zusammenfassung, wie sie aktuell aufgestellt sind: https://wap.eastmoney.com/a/202104171888768516.html Können die beiden "Kanonen" von WuXi die Billionengrenze des Marktwertes durchbrechen?

Noch etwas ausführlicher zur Kurszielerhöhung von JPMorgan Upgrading WuXi Biologics (2269 HK) target price to 130 Hong Kong dollars, rating "overweight" https://m.jrj.com.cn/madapter/hk/2021/04/13110332363528.shtml